Effectiveness and safety of chemotherapy combined with immunomodulatory therapies for multiple myeloma
Abstract. Background:. Multiple myeloma (MM) is considered one of the prevalent malignant plasma cell diseases affecting people. In essence, maintenance treatment is valuable for prolonging the survival time of patients experiencing MM. The majority of the currently used treatment protocols for MM a...
Main Authors: | Jie Deng, MD, Li Liu, MD, Jianhai Sun, MD, Yanlin Ma, MD, Li Li, MD |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer
2022-04-01
|
Series: | Medicine |
Online Access: | http://journals.lww.com/10.1097/MD.0000000000029093 |
Similar Items
-
Oncolytic virotherapy – Forging its place in the immunomodulatory paradigm for Multiple Myeloma
by: Joselle Cook, MD, et al.
Published: (2021-01-01) -
Immunomodulatory Agents for Multiple Myeloma
by: Jiří Minařík, et al.
Published: (2022-11-01) -
A Novel Necroptosis-Related Signature Can Predict Prognosis and Chemotherapy Sensitivity in Multiple Myeloma
by: Jun-Yao Jiang MD, et al.
Published: (2024-02-01) -
Immunomodulatory Compounds (Imids®) in the Treatment of Multiple Myeloma
by: Gordan Srkalovic, et al.
Published: (2009-10-01) -
Central neurotoxicity of immunomodulatory drugs in multiple myeloma
by: Urmeel H. Patel, et al.
Published: (2015-03-01)